glp 1 monoclonal antibody Anti-GLP-1 [EPR4042-407] (ab111125) Targeting GLP-1, GIP & GCG

The current guidelines advise against long-term use for weight control beyond 24 months

Rather than conducting a new meta-analysis, the authors synthesize findings from major randomized clinical trials, highlighting outcomes related to glycated hemoglobin (HbA1c), body weight reduction, major adverse cardiovascular events (MACE), and kidney function decline as reported in large cardiovascular outcomes trials (CVOTs), obesity randomized controlled trials, and early-phase clinical development studies

Bouhlal, S

Ann Rheumatic Dis

We'll follow up with an email confirmation and give you a heads-up once the box has shipped